# First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer

> **NCT06502743** · PHASE2 · RECRUITING · sponsor: **Yonsei University** · enrollment: 92 (estimated)

## Conditions studied

- Endometrial Cancer
- Recurrent Endometrial Carcinoma
- Endometrial Carcinoma
- Gynecologycal Cancer
- Endometrial Neoplasms

## Interventions

- **DRUG:** Nesuparib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06502743
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-12
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2025-04-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06502743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06502743, "First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06502743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*